Application of GHRH-A in preparation of drugs for preventing and treating ischemic brain infarction

A GHRH-A, ischemic brain technology, applied in drug combinations, pharmaceutical formulations, cardiovascular system diseases, etc., can solve the problem of low nerve cell regeneration rate, and achieve the effect of increasing brain weight and improving neurobehavioral performance

Pending Publication Date: 2020-06-02
SHENYANG MEDICAL COLLEGE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the particularity of nerve cell regeneration, the regeneration rate of nerve cells is low, and nerve cell regeneration comes from endogenous neural stem cells in the brain, not bone marrow stem cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of GHRH-A in preparation of drugs for preventing and treating ischemic brain infarction
  • Application of GHRH-A in preparation of drugs for preventing and treating ischemic brain infarction
  • Application of GHRH-A in preparation of drugs for preventing and treating ischemic brain infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0054] Combine the following Figure 1~20 , the content of the present invention is described in detail through specific embodiments.

[0055] The invention relates to the application of growth hormone-releasing hormone receptor agonist MR-409 in the preparation of medicines for preventing and treating ischemic stroke:

[0056] 1. Experimental materials:

[0057] C57BL / 6 mice, male, weighing 22-25 g, animal certificate number: purchased from the Experimental Animal Center of Shenyang Medical College. Adult SD rat, neural stem cells in the hippocampus. MR-409 was provided by the laboratory of Professor Andrew Schally (1977 Nobel Prize winner in medicine) at the University of Miami (Miami, FL, USA), with a purity of 10% 1,2-propanediol. Concentration reserve.

[0058] ,experimental method:

[0059] 2.1 Experimental grouping and administration

[0060] 1) The experimental animals were C57BL / 6 mice, weighing 22-25 g, and divided into sham operation group, model group, MR-409...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the biomedical field, and mainly relates to application of growth hormone releasing hormone receptor agonist MR-409 in preparation of drugs for preventing and treating ischemic brain infarction. The MR-409 is a novel GHRH receptor agonist, and preliminary researches prove that the MR-409 is capable of reducing pathological injury of refractory diseases such as diabetes mellitus and myocardial ischemia by increasing survival of multiple bone marrow stem cells in an ischemic focus. Researches in the invention prove that the MR-409 is capable of remarkably improving ischemic brain injury, survival rate and neurobehavioral manifestations of model mice with cerebral ischemia possibly through a mechanism of increasing proliferation, migration and survival of endogenous neural stem cells. The researches provide new strategies for treatment of the cerebral ischemia, have important clinic treatment significances and provide scientific and theoretical foundations for research and development of drugs utilizing regeneration of nerve cells as cerebral ischemia treating targets in future.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular to the application of growth hormone-releasing hormone receptor agonist (GHRH-A) in the preparation of medicine for preventing and treating ischemic cerebral infarction, and mainly relates to the application of synthetic growth hormone receptor agonist MR-409 Neuroprotective effect and reduction of cerebral infarction sequelae in the prevention and treatment of ischemic cerebral infarction (tMCAO). Background technique [0002] Ischemic cerebral infarction (also known as stroke) is one of the leading causes of death and permanent disability worldwide. At present, the treatment of ischemic cerebral infarction is mainly based on thrombolytic therapy and neuroprotective therapy. Although thrombolytic therapy can achieve vascular recanalization, the best time for thrombolytic therapy is within 6 hours of cerebral infarction. Clinically, most patients have lost the best time for thrombolytic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P9/10A61K38/25
CPCA61K38/16A61K38/25A61P9/10
Inventor 周明生刘月阳安德魯·维克托·沙利蔡仁治蔡瑞平车晓航
Owner SHENYANG MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap